242 related articles for article (PubMed ID: 31099643)
1. Point/Counterpoint: Do We De-escalate Treatment of HPV-Associated Oropharynx Cancer Now? And How?
Wirth LJ; Burtness B; Nathan CO; Grégoire V; Richmon J
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():364-372. PubMed ID: 31099643
[TBL] [Abstract][Full Text] [Related]
2. Treatment de-escalation for HPV-associated oropharyngeal squamous cell carcinoma with radiotherapy vs. trans-oral surgery (ORATOR2): study protocol for a randomized phase II trial.
Nichols AC; Lang P; Prisman E; Berthelet E; Tran E; Hamilton S; Wu J; Fung K; de Almeida JR; Bayley A; Goldstein DP; Eskander A; Husain Z; Bahig H; Christopoulous A; Hier M; Sultanem K; Richardson K; Mlynarek A; Krishnan S; Le H; Yoo J; MacNeil SD; Mendez A; Winquist E; Read N; Venkatesan V; Kuruvilla S; Warner A; Mitchell S; Corsten M; Rajaraman M; Johnson-Obaseki S; Eapen L; Odell M; Chandarana S; Banerjee R; Dort J; Matthews TW; Hart R; Kerr P; Dowthwaite S; Gupta M; Zhang H; Wright J; Parker C; Wehrli B; Kwan K; Theurer J; Palma DA
BMC Cancer; 2020 Feb; 20(1):125. PubMed ID: 32059705
[TBL] [Abstract][Full Text] [Related]
3. De-escalation treatment of human papillomavirus-positive oropharyngeal squamous cell carcinoma: an evidence-based review for the locally advanced disease.
Stock GT; Bonadio RRCC; de Castro G
Curr Opin Oncol; 2018 May; 30(3):146-151. PubMed ID: 29474271
[TBL] [Abstract][Full Text] [Related]
4. Human papillomavirus-associated oropharynx cancer (HPV-OPC): treatment options.
Chau NG; Rabinowits G; Haddad RI
Curr Treat Options Oncol; 2014 Dec; 15(4):595-610. PubMed ID: 25240410
[TBL] [Abstract][Full Text] [Related]
5. Optimizing Treatment De-Escalation in Head and Neck Cancer: Current and Future Perspectives.
Rosenberg AJ; Vokes EE
Oncologist; 2021 Jan; 26(1):40-48. PubMed ID: 32864799
[TBL] [Abstract][Full Text] [Related]
6. HPV-Associated Head and Neck Cancer: Unique Features of Epidemiology and Clinical Management.
Maxwell JH; Grandis JR; Ferris RL
Annu Rev Med; 2016; 67():91-101. PubMed ID: 26332002
[TBL] [Abstract][Full Text] [Related]
7. Prospective study evaluating dynamic changes of cell-free HPV DNA in locoregional viral-associated oropharyngeal cancer treated with induction chemotherapy and response-adaptive treatment.
Rosenberg AJ; Izumchenko E; Pearson A; Gooi Z; Blair E; Karrison T; Juloori A; Ginat D; Cipriani N; Lingen M; Sloane H; Edelstein DL; Keyser K; Fredebohm J; Holtrup F; Jones FS; Haraf D; Agrawal N; Vokes EE
BMC Cancer; 2022 Jan; 22(1):17. PubMed ID: 34980038
[TBL] [Abstract][Full Text] [Related]
8. Has the time come for de-escalation in the management of oropharyngeal carcinoma?
Durkova J; Boldis M; Kovacova S
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2019 Dec; 163(4):293-301. PubMed ID: 31796941
[TBL] [Abstract][Full Text] [Related]
9. Novel Strategies to Effectively De-escalate Curative-Intent Therapy for Patients With HPV-Associated Oropharyngeal Cancer: Current and Future Directions.
Price KAR; Nichols AC; Shen CJ; Rammal A; Lang P; Palma DA; Rosenberg AJ; Chera BS; Agrawal N
Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-13. PubMed ID: 32213088
[TBL] [Abstract][Full Text] [Related]
10. Treatment de-escalation in HPV-positive oropharyngeal carcinoma: ongoing trials, critical issues and perspectives.
Mirghani H; Amen F; Blanchard P; Moreau F; Guigay J; Hartl DM; Lacau St Guily J
Int J Cancer; 2015 Apr; 136(7):1494-503. PubMed ID: 24622970
[TBL] [Abstract][Full Text] [Related]
11. HPV positive oropharyngeal cancer and treatment deintensification: how pertinent is it?
Laskar SG; Swain M
J Cancer Res Ther; 2015; 11(1):6-9. PubMed ID: 25879328
[TBL] [Abstract][Full Text] [Related]
12. De-Escalation After DE-ESCALATE and RTOG 1016: A Head and Neck Cancer InterGroup Framework for Future De-Escalation Studies.
Mehanna H; Rischin D; Wong SJ; Gregoire V; Ferris R; Waldron J; Le QT; Forster M; Gillison M; Laskar S; Tahara M; Psyrri A; Vermorken J; Porceddu S
J Clin Oncol; 2020 Aug; 38(22):2552-2557. PubMed ID: 32496903
[TBL] [Abstract][Full Text] [Related]
13. Postoperative Treatment of Oropharyngeal Cancer in the Era of Human Papillomavirus.
Geiger JL; Ku JA
Curr Treat Options Oncol; 2019 Feb; 20(3):20. PubMed ID: 30771020
[TBL] [Abstract][Full Text] [Related]
14. De-escalation in HPV-associated oropharyngeal cancer: lessons learned from the past? A critical viewpoint and proposal for future research.
Petar S; Marko S; Ivica L
Eur Arch Otorhinolaryngol; 2021 Nov; 278(11):4599-4603. PubMed ID: 33599841
[TBL] [Abstract][Full Text] [Related]
15. De-intensification of therapy in human papillomavirus associated oropharyngeal cancer: A systematic review of prospective trials.
Patel RR; Ludmir EB; Augustyn A; Zaorsky NG; Lehrer EJ; Ryali R; Trifiletti DM; Adeberg S; Amini A; Verma V
Oral Oncol; 2020 Apr; 103():104608. PubMed ID: 32163853
[TBL] [Abstract][Full Text] [Related]
16. HPV-associated oropharyngeal cancer de-escalation strategies and trials: Past failures and future promise.
Zakeri K; Dunn L; Lee N
J Surg Oncol; 2021 Nov; 124(6):962-966. PubMed ID: 34595766
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic strategies: Surgery for human papillomavirus-associated oropharyngeal carcinoma.
Mclean T; Fitzgerald C; Boyle JO
J Surg Oncol; 2021 Nov; 124(6):935-944. PubMed ID: 34595753
[TBL] [Abstract][Full Text] [Related]
18. Societal cost of oropharyngeal cancer by human papillomavirus status, cancer stage, and subsite.
Silfverschiöld M; Sjövall J; Wennerberg J; Östensson E; Greiff L
PLoS One; 2019; 14(7):e0220534. PubMed ID: 31356646
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in the understanding and management of oropharyngeal cancer.
Hay A; Nixon IJ
F1000Res; 2018; 7():. PubMed ID: 30228861
[TBL] [Abstract][Full Text] [Related]
20. Update on De-intensification and Intensification Studies in HPV.
Mehanna H
Recent Results Cancer Res; 2017; 206():251-256. PubMed ID: 27699545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
